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Background: Respiratory pathogens from CF patients can contaminate inpatient settings, which may be associated with increased risk of patient-
to-patient transmission. Few data are available that assess the rate of bacterial contamination of outpatient settings. We determined the frequency
of contamination of CF clinics and the effectiveness of alcohol-based disinfectants in reducing hand carriage of bacterial pathogens.
Methods:We conducted a point prevalence survey and before–after trial in outpatient clinics at 7 CF centers. The study examined CF patients with
positive respiratory cultures for Pseudomonas, Staphylococcus, Stenotrophomonas or Burkholderia species. Hand carriage and environmental
contamination with respiratory pathogens were assessed during clinic visits (Part I) and the effectiveness of hand hygiene performed by CF
patients (Part II) was determined using molecular typing of recovered isolates.
Results: In Part I (n=97), the contamination rate was 13.6%. Pseudomonas and S. aureus, including methicillin-resistant strains, were cultured from
patients' hands (7%), the exam room air (8%), and less commonly, environmental surfaces (1%). In Part II (n=100), the hand carriage rate of
pathogens was 13.5% and 4 participants without initial detection of pathogens had hand contamination when recultured at the end of the clinic visit.
Conclusions: Respiratory pathogens from CF patients can contaminate their hands and the clinic environment, but the actual risk of patient-to-
patient transmission in the outpatient setting remains difficult to quantify. These findings support several recommendations CF infection control
recommendations including hand hygiene for staff and patients, contact precautions for certain pathogens, and disinfecting equipment and surfaces
touched by patients and staff.
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Chronic infections of the respiratory tract are well-recog-
nized complications of cystic fibrosis (CF). Though consider-
able resources are expended to manage exacerbations of
pulmonary disease, over time, a progressive decline in
pulmonary function occurs and ultimately is the leading cause
of death. Patients with CF are infected with predictable
pathogens including Pseudomonas aeruginosa (PA), Staphylo-
coccus aureus (SA), and Burkholderia species. While the
source of these pathogens is often unknown, there is ampled by Elsevier B.V. All rights reserved.
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bacteria in non-healthcare settings in which extensive social
contact occurs, such as summer camps or households [1–7] and
on inpatient CF units [8–15]. Respiratory tract pathogens from
CF patients can survive on inanimate surfaces and contaminate
the inpatient hospital environment where patient residency is
prolonged [16–20]. Direct and indirect evidence of patient-to-
patient spread of Burkholderia dolosa and Pseudomonas sp.,
respectively, within CF clinic populations has been reported
[21,22]. However, fewer studies have directly assessed the risk
of contamination of outpatient facilities [23]. The need for
additional data for outpatient settings was highlighted in a
consensus document on infection control for CF patients [24],
which suggested that further study was warranted to develop
evidence-based standards for best practices in CF clinics. This
information gap formed the basis for the current investigation
which sought to test two hypotheses: [1] during office visits,
respiratory pathogens from CF patients contaminate the hands
of patients and healthcare professionals as well as the air and
environmental surfaces in examination rooms. [2] Alcohol-
based hand hygiene disinfectants reduce the rate of patient hand
carriage of respiratory pathogens. Some results of these results
have been reported in abstract form [25–27].
2. Methods
2.1. Study design
In Part I, we sought to determine how frequently the
respiratory pathogens of CF patients would be recovered from
their hands, the hands of CF team members, the air, or
environmental surfaces within examination rooms where
patients were evaluated during CF outpatient visits. In Part II,
we assessed if hand hygiene performed by CF patients using
alcohol-based rubs reduced their hand carriage of respiratory
pathogens.
2.2. Study sites and study participants
Seven CF Centers, caring for approximately 600 CF patients,
received Institutional Review Board approval to participate in
this study. Eligible participants were ≥6 years of age with a
history of sputum production and previous cultures for SA, PA,
Stenotrophomonas maltophilia (SM), and/or Burkholderia
cepacia complex (BCC). Potential subjects were recruited
during CF clinic visits, and all participants signed consent prior
to enrollment.
2.3. Sampling techniques for CF respiratory pathogens
2.3.1. Respiratory tract cultures
Pulmonary function testing was performed in the examination
room and then either an expectorated sputum or oropharyngeal
culture (if sputum was not produced) was obtained. The sites'
study team sampled the specimen using a rayon-tipped swab
(Remel, Lenexa, KS) which was sent in modified Stewart's
medium to the core microbiology laboratory for study purposes.2.3.2. Environmental cultures
Prior to each CF clinic session in Part I, environmental
cultures were collected in the study examination rooms using a
premoistened swab. Sites included sinks, door handles, stetho-
scopes, and otoscopes. During the study visits, these sites were
cultured within 10 min of the participant leaving the room and
prior to cleaning the room. At the end of the clinic session,
common areas including the bathroom, arm chairs in the waiting
area and toys were cultured.
2.3.3. Air sampling
Air sampling was performed with a single-stage impactor
hooked in series to a vacuum pump (1-STG Viable Particle
Sampler, Andersen Instruments Inc., Atlanta, GA) with a
collection rate of 28.3 l of air per minute. Prior to clinic, the
examination room air was sampled for 30 min onto a blood agar
plate. During study visits, the impactor was placed 3 ft in front
of the participant and the air was sampled throughout the visit.
The participants moved about the room as was customary for
each study site. The air sample was estimated to be 4.3–23.5%
of the volume of each examination room.
2.3.4. Hand cultures
In Part I, staff hands were cultured before clinic and after
participant encounters, and participants' hands were cultured
prior to performing hand hygiene as previously described [28].
2.3.5. Recovery experiments
To assess the sensitivity of each of the culturing techniques
used in the study, several recovery experiments were performed.
Broth culture suspensions of 105 colony forming units (CFU)
per ml of the organisms of interest (i.e., PA, SA, SM and BCC),
were prepared using a colorimeter and serial dilutions weremade
(range 101–105 CFU/ml). In the first experiment, 0.5 ml of each
dilution was inoculated onto a dry laboratory bench covering an
area 10 cm by 10 cm. After 5 min, the area was sampled with a
pre-moistened swab. In the second experiment, 0.5 ml of each
dilution was nebulized for 5 min (0.84 cm3) from a Pari-LC
nebulizer driven by a Pulmo-Aide compressor. The mouthpiece
of the nebulizer was placed 12 in. from the inlet of the impactor
and samples were collected onto a blood agar plate. The level of
detection for each of these recovery experiments was approxi-
mately 102 CFU (data not shown). Recovery experiments were
also performed for “glove juice” sampling. An inoculum of the
designated organism in log phase growth was prepared in 50 ml
of sampling buffer. The sample was refrigerated overnight to
duplicate the transport conditions required for specimens sent to
the core laboratory. The sampling buffer was then centrifuged
and suspensions of the pellet were diluted and plated. The level
of detection by this method was approximately 102 CFU for each
study organism (data not shown).
2.3.6. Hand decontamination with alcohol-based disinfectant
In Part II, the effectiveness of hand hygiene in reducing hand
carriage of respiratory pathogens was studied. Participants from
Part I were eligible for Part II, but were recruited at a different clinic
visit. Participant handswere cultured at the start of the visit and then
Table 1
Comparison of participant characteristics in Part I and Part II.
Participant characteristics Part I Part II
N=97 N=100
Pediatric participant 47 (48%) 50 (50%)
Study organism in respiratory culture 83 (86%) 74 (74%)
Study organism isolated⁎
PA 52% 38%
SA 40% 50%
BCC 6% 2%
SM 11% 8%
Pulmonary exacerbation 28 (29%) 14 (14%)
⁎Some participants had more than one pathogen isolated from their respiratory tract.
Table 2
Distribution of pathogens in Part I in pre-clinic, study visit, and post-clinic
cultures.
Culture sites Cultures
obtained (#)
PA a MSSA MRSA BCC SM
Pre-clinic cultures
Staff hands 165 8 5 1 0 0
Examination room air 55 3 2 0 1 0
Environmental surfaces 330 2 2 0 0 0
Post-clinic cultures 252 5 7 0 0 0
Total pre- and post-clinic
cultures
802 18 16 1 1 0
Study visit b
Participant hands 97 3 1 2 0 0
Staff hands 291 0 0 0 0 0
Examination room air 97 4 3 1 0 0
Environmental surfaces 1067 0 0 1 0 0
Total study visit cultures 1552 7 4 4 0 0
a Abbreviations used in table: PA — P. aeruginosa, MSSA — methicillin
susceptible S. aureus, MRSA — methicillin resistant S. aureus, BCC —
B. cepacia complex, SM — S. maltophilia.
b Study visit culture results show PFGE-confirmed matches.
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at each site, according to the manufacturers' instructions. At the
completion of visits, participant hands were re-cultured.
2.4. Microbiology and molecular epidemiology
Specimens were transported overnight on ice to the core
laboratory and processed in accordance with CF Foundation
guidelines [29]. Isolates of BCC were sent to the U.S. CF
Foundation B. cepacia Research Laboratory and Repository for
confirmation of identity [30]. If the same species was recovered
from a participant's respiratory tract and from environmental,
air, and/or hand cultures obtained during their study visit, then
each potential match was analyzed by pulsed field gel
electrophoresis (PFGE), as previously described using the
following restriction enzymes for the target organisms: SA —
SmaI; PA — SpeI; SM — XbaI; BCC — SpeI)[31]. Strains
were considered “indistinguishable” if the band patterns were
identical, “probably related” if there was a 1–2 band difference,
“possibly related” if there was a 3–4 band difference, and
“unrelated” if there was N4 band difference [32]. If a strain(s)
from a participant's respiratory tract was indistinguishable,
probably or possibly related to any relevant strain(s) from
environmental surfaces, hands, or air, this was interpreted as a
match consistent with bacterial contamination of the CF clinic.
2.5. Assessment of potential risk factors associated with
bacterial contamination
To test the hypothesis that clinical factors might associate with
an increased risk of bacterial contamination, the following were
collected, as previously described, to assess for pulmonary
exacerbations [33]: presence of fever or hemoptysis, and changes
in the reported severity of cough, reported daily sputum volume,
forced expiratory volume in one second (FEV1), weight,
oxyhemoglobin saturation, and chest radiograph (if performed).
Determination of protocol-defined pulmonary exacerbation was
made by site investigators at the time of study encounters.
2.5.1. Statistical methods
Exact confidence intervals were calculated using the
binomial distribution. Chi-square or Fischer's exact tests wereused to test the associations of clinical factors and bacterial
contamination. The analyses were done using Stata Statistical
Software, version 9.2, College Station, TX: Stata Corporation,
2006. A sample size of 100 subjects for Part I of the study
provided 90% power to detect a contamination rate of 3% by
any study organism.
3. Results
In Part I, 97 participants were enrolled from 7 study sites
(median 10 participants per site, range 6–36). In Part II, 100
participants were enrolled from 6 of these sites (median 15
participants per site, range 6–34). Participant characteristics
including their respiratory pathogens are shown (Table 1). The
median duration of study visits was 72 min (range 60–170 min).
In Part I, 97 participants were enrolled during 55 clinic
sessions and 1887 cultures were obtained. These included 605
pre-clinic cultures, 1030 visit cultures, and 252 post-clinic
cultures. Potential respiratory pathogens were recovered from
both the pre-clinic and post-clinic cultures (Table 2). The rate of
positive pre-clinic cultures varied among the sites from 0% to
11% (mean 4.7%; 95% CI, 3.3%–6.8%). Surfaces of instru-
ments such as pulse oximeters, stethoscopes and otoscopes were
rarely contaminated; PA and SA were each recovered from a
pre-clinic culture of a stethoscope. The rate of positive post-
clinic cultures among the sites ranged from 0% to 10.9% (mean
3.6%; 95% CI, 1.9–6.6%). Respiratory pathogens were detected
on receptionists' counters, bathroom faucets, and waiting room
chairs. Pre- and post-clinic cultures were not evaluated with
PFGE for matching with participants' respiratory tract patho-
gens, as these were obtained in common areas frequented by
study and non-study patients.
In Part I, 81 participants had a pathogen of interest isolated
from their respiratory tract which included 38 potential matches.
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resulting in a contamination rate of 13.6% (95% CI, 6.8–
22.5%), as shown in Table 2 and Fig. 1. During 5 (6.2%)
encounters, contamination of environmental surfaces or air was
detected. The contamination rate varied among study sites from
0% (one site) to 33%, but site differences were not statistically
significant due to sample size.
With 3 participants more than one site was contaminated by a
protocol-defined match. Methicillin-resistant SA (MRSA) was
recovered from a participant's hands, air culture, and a pulse
oximeter; both methicillin-susceptible SA (MSSA) and PAwere
recovered from the examination room air of another participant;
and MSSAwas recovered from a participant's hands and the air.
During 10 study visits, air cultures grew bacteria (4 MSSA, 1
MRSA, and 5 PA) that did not match the participant's respiratory
tract isolates. There were no significant differences in the
contamination rates between adult versus pediatric participants
(14.0% vs. 12.5%, respectively, p=0.552) nor between partici-
pants with and without signs and symptoms of a pulmonary
exacerbation (13.8% and 12.5%, respectively, p=1.0). No
contamination was observed from participants harboring BCC.
In Part II, 74 participants had an organism of interest isolated
from their respiratory tract and potential respiratory pathogens
were recovered from some of their hands. Prior to alcohol-based
hand hygiene, MSSA (n=6), PA (n=3), MRSA (n=7) and SM
(n=1) were recovered and at the end of the study visit, MSSA
(n=7), PA (n=4), MRSA (n=7) and SM (n=2) were recovered.
PFGE results revealed that the respiratory pathogens of 13.5%Fig. 1. Representative PFGE gels from Part I of the study comparing respiratory and e
a single participant encounter with indistinguishable band pattern. Lane 1: sputum iso
aureus isolates from a single clinic showing unrelated band patterns. Lane 1: pre-clini
staff hand isolate Lane 4: participant sputum isolate Lane 5: air isolate. Panel C. Pseud
band patterns. Lane 1: sputum isolate Lane 2: sputum isolate Lane 3: air isolate.(10/74) of participants were cultured from their hands prior to
hand hygiene. At the end of the study visit, five of these
participants had decontaminated their hands, but four additional
patients had new detection of matched pathogens on their hands
at the end of the visit (Fig. 2). In Part II there was a trend toward
increased hand carriage in ill (28.6%, 95% CI 11.8–55%) vs.
versus stable (11.6%, 95% CI 6.5–20.0%) patients (p=0.10).
4. Discussion
Providing effective infection control at CF centers is an
important issue, as reports accrue about potential routes of
transmission of respiratory pathogens within this susceptible
patient population. However, the relative lack of data for the
outpatient clinic setting has, in part, resulted in varying infection
control policies at different CF Centers [34]. To our knowledge,
this is the first systematic, multicenter study utilizing molecular
typing to determine the rate of bacterial contamination of CF
clinics with patient pathogens. The results of the current study
are likely to be generalizable, as the study was conducted in a
variety of practice settings including university-based clinics as
well as office-based practices. Though study sites differed in the
duration of clinic visits, team composition and number of
patients seen per clinic, there was general conformity to certain
practices: 1) patients were not required to wear masks 2) effort
was made to minimize waiting room time for patients, and 3)
spirometry was performed in the examination room, not in free-
standing laboratory spaces.nvironmental isolates by PFGE. Panel A. Pseudomonas aeruginosa isolates from
late Lane 2: air isolate Lane 3: participant hand isolate. Panel B. Staphylococcus
c air isolate Lane 2: post-clinic bathroom faucet handle isolate Lane 3: pre-clinic
omonas aeruginosa isolates from a single patient encounter with possibly related
Fig. 2. Flow diagram of contamination events in Part I and Part II. This figure shows the rates of isolation of the pathogens of interest from the respiratory tract of
participants. For Part I the proportion of participants with available and unavailable isolates, the PFGE study-defined matches, and the source of isolates that matched
participants' respiratory isolates are shown. For Part II, the proportion of participants with available and unavailable isolates and PFGE matches before hand hygiene
and at the end of study visits are shown.
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of 11 PFGE-defined matches in Part I and by study design, 14 of
14 matches in Part II) was most common. Unfortunately, hand
hygiene performed at the start of clinic did not prevent
subsequent contamination of the hands during study visits, as
4 participants had pathogens detected on their hands at the end
of the visit that were not identified at the start. We do not believe
this observation is due to ascertainment bias, as glove juice
recovery experiments demonstrated a level of detection of 102
colony forming units (CFU). The finding is likely attributable to
contamination of the hands during the visit and inability of
alcohol rubs to prevent subsequent acquisition of viable
organisms. This confirms that frequent hand hygiene should
be performed throughout clinic visits.
In the current era of multidrug-resistant bacteria, attention
has focused on the role of the environment as a reservoir for
potential pathogens, particularly in the healthcare setting
[35,36]. Respiratory secretions from clinically stable CF
patients contain a heavy burden of bacteria, typically 107–
108 CFU/g of sputum in adults and 104–105 CFU/g in young
children [37,38]. Patient care equipment, including respiratory
devices [39], can therefore harbor potential pathogens. As has
been previously reported [40], we found that stethoscopes and
pulse oximeters can become contaminated in the clinic, though
infrequently. While specimens collected during the study visit
could be definitively linked with a participant's respiratory
tract, potential pathogens recovered from common sites in the
clinic could not be matched with a specific subject due to the
study design. Taken together, our results support consensusguideline recommendations for disinfecting horizontal surfaces
in healthcare settings serving CF patients [24,41], though CF
centers face the challenge of maintaining adequate staff to clean
exam rooms between patients [42].
We found that the contamination rates of participants with
and without pulmonary exacerbation were similar. This finding
corroborates published statements emphasizing that all CF
patients may harbor transmissible pathogens and supports the
practice of cough etiquette described in recent infection control
consensus guidelines [24] and in revised guidelines for source
containment of potential pathogens [43].
In this investigation, isolates from study participants were
recovered from air in the exam rooms. Infectious droplets are
known to be a mode of person-to-person spread of viral and
bacterial pathogens [43] and have been linked to transmission in
CF [24]. Other studies have detected organisms in the air of
rooms in which CF patients received care as long as 45 min after
they had left the room [44]. The infection control guidelines
recommend that CF patients remain at least 3 ft apart to
minimize droplet transmission, although recent data suggests
that droplets may travel as far as 6–10 ft [43]. When respiratory
droplets are aerosolized, transmission is more likely. The
duration of time that droplets harboring viable bacteria may be
suspended in the air varies and depends on both droplet
characteristics and environmental characteristics such as
humidity and temperature [43,45]. The infection control
guidelines for CF currently consider the universal use of
masks for CF patients to be an unresolved issue, as outbreaks in
this population have been halted without the use of masks [46].
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and the potential infectivity of suspended droplets.
Some limitations were identified in this study. Enrollment
criteria stipulated that patients have a history of producing
sputum harboring an organism of interest. However, not all
patients were able to provide sputum samples during the study
visit (Table 1), and not all respiratory specimens grew a study
pathogen. Our molecular typing definition for a “match” could
have misclassified strains exhibiting clonal variation. Finally,
the study was not adequately powered to examine the effect of
pulmonary exacerbation on hand contamination.
The actual risk of patient-to-patient transmission of CF
pathogens within the CF clinic remains difficult to quantify, as
long-term observations of many patients utilizing costly methods
such as those described in this studywould be needed. In addition,
patient acquisition of a new respiratory pathogen would not
distinguish transmission from the clinic from transmission that
occurred during contact elsewhere. Nevertheless, it would appear
to be a worthy goal to minimize contamination of CF clinics in
ways that are practical and effective without jeopardizing the
demonstrated benefits of care provided by CF teams [47].
This study, performed at a variety of CF centers, demon-
strated a measurable contamination rate of patients' hands and
the clinic environment. We confirmed that the use of alcohol-
based hand hygiene products effectively reduced hand carriage
of respiratory pathogens, but also found that repeated hand
hygiene during office visits is needed to control the risk of
recurrent contamination.
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